PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Creative Biolabs

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Creative Biolabs Announces Bi-specific Antibody Production - In order to increase the efficacy of current therapeutic antibodies, Creative Biolavs, an industry leader in the field of antibody engineering field, has developed CeativeAbTM antibodies - Creative-Biolabs.com
Creative Biolabs Announces Bi-specific Antibody Production

 

NewswireToday - /newswire/ - Shirley, NY, United States, 2015/09/10 - In order to increase the efficacy of current therapeutic antibodies, Creative Biolavs, an industry leader in the field of antibody engineering field, has developed CeativeAbTM antibodies - Creative-Biolabs.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bi-specific antibodies (BsAbs) are bioengineered antibodies that contain two different binding sites within a single molecule, which can specifically bind two different types of antigens. The most widely used application of bi-specific antibody is in cancer immunotherapy, which creates a therapeutic treatment approach for diseases with specific medical needs.

Compared with traditional antibodies, bi-specific antibodies have many advantages. The two arms can bring an antigen-expressing cell in close proximity to a killing cell, thus destroy the tumor cell. By binding to two different epitopes on an antigen, these two binding sites can significantly increase affinity or internalization rates of particular antigens on a cell's surface. They usually have a higher cytotoxic potential to bind to antigens with low expression level. Binding tumor cells utilizing a bi-specific antibody-drug conjugate (ADC) also holds great promise for the future development of therapeutics in various diseases.

With the development of antibody engineering, many types of bi-specific antibodies have been designed to enable short half-life, immunogenicity and side-effects caused by cytokine liberation. They include tri-functional antibodies, chemically linked Fabs and various types of bivalent and trivalent single-chain variable fragments (scFvs) and fusion proteins mimicking the variable domains of two antibodies. The furthest developed of these newer formats are the bi-specific T-cell engagers (BiTEs) and mAb2's, antibodies engineered to contain an Fcab antigen-binding fragment instead of the Fc constant region.

Creative Biolabs offers various types of bi-specific antibodies, including tri-functional antibodies and chemically linked Fabs, bivalent and bi-specific scFvs (tandem scFv, diabodies), bi-specific T-cell engagers (BiTEs) and scFv-Fab fusion proteins.

Based on various antibody formats such as IgGs, Fabs and scFvs, our Creative Discovery Platform™ provides a series of bi-specific antibodies to satisfy various customers' needs. We provide construction (expression & purification) as well as recombinant antibody production at scales£ ranging from hundreds of micrograms to grams level.

About Creative Biolabs

Creative Biolabs (creative-biolabs.com) is specialized in providing custom biotechnology and pharmaceutical services that cover the full scope of biotechnology needs of early drug discovery and drug development. As a trusted provider of the most cost-effective outsourcing solutions, Creative Biolabs has been working for a large number of satisfied clients from biotechnology and pharmaceutical companies as well as government and academic research laboratories all over the world. learn more about Creative Biolabs.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Creative Biolabs

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Creative Biolabs Announces Bi-specific Antibody Production

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Candy Swift - Creative-Biolabs.com 
631-871-5806 contact[.]creative-biolabs.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Creative Biolabs securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Creative Biolabs / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)